Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-c-Met antibody-drug conjugate BYON3521

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) site-specifically conjugated to a linker-duocarmycin payload, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC BYON3521, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding, the linker is cleaved inside the tumor thereby releasing the duocarmycin payload. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death in c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.
Synonym:ADC BYON3521
anti-c-Met ADC BYON3521
anti-c-Met/duocarmycin antibody-drug conjugate BYON3521
Code name:BYON 3521
BYON-3521
BYON3521
Search NCI's Drug Dictionary